Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709207 | 0.95 | PARP14 (0.43) | PARP14LMNAIDO1PLA2G7TYMS | |
| SCHEMBL6707812 | 0.92 | PARP14 (0.38) | PARP14PLA2G7TYMS | |
| SCHEMBL6713884 | 0.92 | PARP14 (0.39) | PARP14PLA2G7MEN1KMT2ANSD2 | |
| SCHEMBL6707895 | 0.92 | PARP14 (0.39) | PARP14LMNAPLA2G7TYMSMEN1 | |
| SCHEMBL6710454 | 0.92 | PARP14 (0.41) | PARP14LMNAAKT1EGLN1MEN1 | |
| SCHEMBL6711934 | 0.92 | PRSS12 (0.39) | PLA2G7MEN1KMT2ANSD2 | |
| SCHEMBL6713683 | 0.91 | PARP14 (0.37) | PARP14 | |
| SCHEMBL6710270 | 0.91 | NR1H4 (0.39) | PARP14PLA2G7 | |
| SCHEMBL6708759 | 0.90 | CACNA1H (0.37) | PARP14AKT1IDO1TYMS | |
| SCHEMBL6710328 | 0.90 | PARP14 (0.41) | PARP14PLA2G7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | PARP14 2597/4885LMNA 4062/4885AKT1 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.